VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q110226399  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241120235717.0
008     241120nneanz||abbn n and d
035 ‎‡a  (WKP)Q110226399‏
035 ‎‡a  (OCoLC)Q110226399‏
100 0 ‎‡a  David R. Jones‏ ‎‡c  pharmacology researcher at Indiana University‏ ‎‡9  en‏
670 ‎‡a  Author's A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies.‏
670 ‎‡a  Author's A phase I dose escalation and pharmacokinetic study of vatalanib‏
670 ‎‡a  Author's A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors‏
670 ‎‡a  Author's A Phase I Trial of High-Dose Clofarabine, Etoposide, and Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation in Patients with Primary Refractory and Relapsed and Refractory Non-Hodgkin Lymphoma‏
670 ‎‡a  Author's A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157.‏
670 ‎‡a  Author's A pilot study of the impact of genotype on nifedipine pharmacokinetics when used as a tocolytic‏
670 ‎‡a  Author's Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity‏
670 ‎‡a  Author's ATPS-75TARGETING THE Mdm2-Akt SIGNALING NETWORK IN COMBINATION WITH TEMOZOLOMIDE IMPROVES EFFICACY IN ECTOPIC AND ORTHOTOPIC PATIENT-DERIVED GLIOBLASTOMA XENOGRAFT MODELS.‏
670 ‎‡a  Author's Chemopreventative celecoxib fails to prevent schwannoma formation or sensorineural hearing loss in genetically engineered murine model of neurofibromatosis type 2.‏
670 ‎‡a  Author's Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers‏
670 ‎‡a  Author's Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist‏
670 ‎‡a  Author's Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.‏
670 ‎‡a  Author's Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment‏
670 ‎‡a  Author's Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5).‏
670 ‎‡a  Author's Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz.‏
670 ‎‡a  Author's CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer‏
670 ‎‡a  Author's Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance‏
670 ‎‡a  Author's Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil‏
670 ‎‡a  Author's Differential modulation of UDP-glucuronosyltransferase 1A1‏
670 ‎‡a  Author's Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes‏
670 ‎‡a  Author's Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer‏
670 ‎‡a  Author's Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation‏
670 ‎‡a  Author's Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes‏
670 ‎‡a  Author's EXTH-13. REDUCTION OF TUMOR BURDEN AND HEARING LOSS WITH A MULTIPLE RECEPTOR TYROSINE KINASE INHIBITOR BRIGATINIB IN A GENETICALLY ENGINEERED MOUSE MODEL OF NEUROFIBROMATOSIS TYPE 2‏
670 ‎‡a  Author's Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity‏
670 ‎‡a  Author's Impact of APE1/Ref-1 redox inhibition on pancreatic tumor growth‏
670 ‎‡a  Author's In vitro effect of chlorambucil on human glioma cell lines (SF767 and U87-MG), and human microvascular endothelial cell (HMVEC) and endothelial progenitor cells (ECFCs), in the context of plasma chlorambucil concentrations in tumor-bearing dogs‏
670 ‎‡a  Author's In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles‏
670 ‎‡a  Author's In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies‏
670 ‎‡a  Author's Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in rats‏
670 ‎‡a  Author's Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of Nf1-Deficient Mice‏
670 ‎‡a  Author's Mechanism-based inactivation of CYP3A by HIV protease inhibitors‏
670 ‎‡a  Author's Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients‏
670 ‎‡a  Author's Pharmacokinetics of Cefepime in Patients with Cancer and Febrile Neutropenia in the Setting of Hematologic Malignancies or Hematopoeitic Cell Transplantation.‏
670 ‎‡a  Author's Phase I, pharmacogenomic, drug-interaction study of sorafenib and bevacizumab in combination with paclitaxel in patients with advanced refractory solid tumors‏
670 ‎‡a  Author's Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens.‏
670 ‎‡a  Author's Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1.‏
670 ‎‡a  Author's Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites‏
670 ‎‡a  Author's Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition‏
670 ‎‡a  Author's Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial‏
670 ‎‡a  Author's Quantification of vincristine and its major metabolite in human plasma by high-performance liquid chromatography/tandem mass spectrometry‏
670 ‎‡a  Author's Relationship among histologic, radiologic, and biochemical assessments of hepatic steatosis: a study of human liver samples‏
670 ‎‡a  Author's Relationship between differential hepatic microRNA expression and decreased hepatic cytochrome P450 3A activity in cirrhosis‏
670 ‎‡a  Author's Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite.‏
670 ‎‡a  Author's Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis‏
670 ‎‡a  Author's Stereoselective Analysis of Methadone and EDDP in Laboring Women and Neonates in Plasma and Dried Blood Spots and Association with Neonatal Abstinence Syndrome‏
670 ‎‡a  Author's Stereoselective Glucuronidation of Bupropion Metabolites In Vitro and In Vivo‏
670 ‎‡a  Author's Stereoselective method to quantify bupropion and its three major metabolites, hydroxybupropion, erythro-dihydrobupropion, and threo-dihydrobupropion using HPLC-MS/MS‏
670 ‎‡a  Author's Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity‏
670 ‎‡a  Author's The cytochrome P450 2B6‏
670 ‎‡a  Author's The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity‏
670 ‎‡a  Author's The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry‏
670 ‎‡a  Author's Tissue Transglutaminase Activates Cancer-Associated Fibroblasts and Contributes to Gemcitabine Resistance in Pancreatic Cancer‏
670 ‎‡a  Author's Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis‏
919 ‎‡a  phase1trialofhighdoseclofarabineetoposideandcyclophosphamideandautologousperipheralbloodstemcelltransplantationinpatientswithprimaryrefractoryandrelapsedandrefractorynonhodgkinlymphoma‏ ‎‡A  A Phase I Trial of High-Dose Clofarabine, Etoposide, and Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation in Patients with Primary Refractory and Relapsed and Refractory Non-Hodgkin Lymphoma‏ ‎‡9  1‏
919 ‎‡a  phase1doseescalationandpharmacokineticstudyofvatalanib‏ ‎‡A  A phase I dose escalation and pharmacokinetic study of vatalanib‏ ‎‡9  1‏
919 ‎‡a  phase1andpharmacokinetictrialoferlotinibincombinationwithweeklydocetaxelinpatientswithtaxanenaivemalignancies‏ ‎‡A  A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies.‏ ‎‡9  1‏
919 ‎‡a  phase1doseescalationandpharmacokineticstudyofvatalanibptk787zk222584incombinationwithpaclitaxelinpatientswithadvancedsolidtumors‏ ‎‡A  A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors‏ ‎‡9  1‏
919 ‎‡a  virtualscreeningtargetingtheurokinasereceptorbiochemicalandcellbasedstudiessynthesispharmacokineticcharacterizationandeffectonbreasttumormetastasis‏ ‎‡A  Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis‏ ‎‡9  1‏
919 ‎‡a  tissuetransglutaminaseactivatescancerassociatedfibroblastsandcontributestogemcitabineresistanceinpancreaticcancer‏ ‎‡A  Tissue Transglutaminase Activates Cancer-Associated Fibroblasts and Contributes to Gemcitabine Resistance in Pancreatic Cancer‏ ‎‡9  1‏
919 ‎‡a  quantificationoferlotinibosi774andosi420inhumanplasmabyliquidchromatographytandemmassspectrometry‏ ‎‡A  The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry‏ ‎‡9  1‏
919 ‎‡a  cytochromep4502b6cyp2b6isthemaincatalystofefavirenzprimaryandsecondarymetabolismimplicationforhivaidstherapyandutilityofefavirenzasasubstratemarkerofcyp2b6catalyticactivity‏ ‎‡A  The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity‏ ‎‡9  1‏
919 ‎‡a  cytochromep4502b6‏ ‎‡A  The cytochrome P450 2B6‏ ‎‡9  1‏
919 ‎‡a  tamoxifendoseescalationinpatientswithdiminishedcyp2d6activitynormalizesendoxifenconcentrationswithoutincreasingtoxicity‏ ‎‡A  Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity‏ ‎‡9  1‏
919 ‎‡a  stereoselectivemethodtoquantifybupropionandits3majormetaboliteshydroxybupropionerythrodihydrobupropionandthreodihydrobupropionusinghplcmsms‏ ‎‡A  Stereoselective method to quantify bupropion and its three major metabolites, hydroxybupropion, erythro-dihydrobupropion, and threo-dihydrobupropion using HPLC-MS/MS‏ ‎‡9  1‏
919 ‎‡a  stereoselectiveglucuronidationofbupropionmetabolitesinvitroandinvivo‏ ‎‡A  Stereoselective Glucuronidation of Bupropion Metabolites In Vitro and In Vivo‏ ‎‡9  1‏
919 ‎‡a  stereoselectiveanalysisofmethadoneandeddpinlaboringwomenandneonatesinplasmaanddriedbloodspotsandassociationwithneonatalabstinencesyndrome‏ ‎‡A  Stereoselective Analysis of Methadone and EDDP in Laboring Women and Neonates in Plasma and Dried Blood Spots and Association with Neonatal Abstinence Syndrome‏ ‎‡9  1‏
919 ‎‡a  smallmoleculeinhibitionoftheuparupainteractionsynthesisbiochemicalcellularinvivopharmacokineticsandefficacystudiesinbreastcancermetastasis‏ ‎‡A  Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis‏ ‎‡9  1‏
919 ‎‡a  semiphysiologicallybasedpharmacokineticmodelsfortheinhibitionofmidazolamclearancebydiltiazemanditsmajormetabolite‏ ‎‡A  Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite.‏ ‎‡9  1‏
919 ‎‡a  relationshipbetweendifferentialhepaticmicrornaexpressionanddecreasedhepaticcytochromep4503aactivityincirrhosis‏ ‎‡A  Relationship between differential hepatic microRNA expression and decreased hepatic cytochrome P450 3A activity in cirrhosis‏ ‎‡9  1‏
919 ‎‡a  relationshipamonghistologicradiologicandbiochemicalassessmentsofhepaticsteatosisastudyofhumanliversamples‏ ‎‡A  Relationship among histologic, radiologic, and biochemical assessments of hepatic steatosis: a study of human liver samples‏ ‎‡9  1‏
919 ‎‡a  quantificationofvincristineanditsmajormetaboliteinhumanplasmabyhighperformanceliquidchromatographytandemmassspectrometry‏ ‎‡A  Quantification of vincristine and its major metabolite in human plasma by high-performance liquid chromatography/tandem mass spectrometry‏ ‎‡9  1‏
919 ‎‡a  quantificationoftamoxifenand3metabolitesinplasmabyhighperformanceliquidchromatographywithfluorescencedetectionapplicationtoaclinicaltrial‏ ‎‡A  Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial‏ ‎‡9  1‏
919 ‎‡a  predictionoftheeffectoferythromycindiltiazemandtheirmetabolitesaloneandincombinationoncyp3a4inhibition‏ ‎‡A  Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition‏ ‎‡9  1‏
919 ‎‡a  predictionofcytochromep4503ainhibitionbyverapamilenantiomersandtheirmetabolites‏ ‎‡A  Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites‏ ‎‡9  1‏
919 ‎‡a  preclinicalassessmentsofthemekinhibitorpd0325901inamousemodelofneurofibromatosistype1‏ ‎‡A  Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1.‏ ‎‡9  1‏
919 ‎‡a  populationpharmacokineticsofcefepimeinfebrileneutropeniaimplicationsfordosedependentsusceptibilityandcontemporarydosingregimens‏ ‎‡A  Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens.‏ ‎‡9  1‏
919 ‎‡a  phase1pharmacogenomicdruginteractionstudyofsorafenibandbevacizumabincombinationwithpaclitaxelinpatientswithadvancedrefractorysolidtumors‏ ‎‡A  Phase I, pharmacogenomic, drug-interaction study of sorafenib and bevacizumab in combination with paclitaxel in patients with advanced refractory solid tumors‏ ‎‡9  1‏
919 ‎‡a  pharmacokineticsofcefepimeinpatientswithcancerandfebrileneutropeniainthesettingofhematologicmalignanciesorhematopoeiticcelltransplantation‏ ‎‡A  Pharmacokinetics of Cefepime in Patients with Cancer and Febrile Neutropenia in the Setting of Hematologic Malignancies or Hematopoeitic Cell Transplantation.‏ ‎‡9  1‏
919 ‎‡a  pharmacokineticandpharmacodynamicalterationsintherouxenygastricbypassrecipients‏ ‎‡A  Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients‏ ‎‡9  1‏
919 ‎‡a  mechanismbasedinactivationofcyp3abyhivproteaseinhibitors‏ ‎‡A  Mechanism-based inactivation of CYP3A by HIV protease inhibitors‏ ‎‡9  1‏
919 ‎‡a  ketotifenmodulatesmastcellchemotaxistokitligandbutdoesnotimpactmastcellnumbersdegranulationortumorbehaviorinneurofibromasofnf1deficientmice‏ ‎‡A  Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of Nf1-Deficient Mice‏ ‎‡9  1‏
919 ‎‡a  inhibitionofcyp3abyerythromycininvitroinvivocorrelationinrats‏ ‎‡A  Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in rats‏ ‎‡9  1‏
919 ‎‡a  invivodpp4inhibitiontoenhanceengraftmentofsingleunitcordbloodtransplantsinadultswithhematologicalmalignancies‏ ‎‡A  In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies‏ ‎‡9  1‏
919 ‎‡a  invivoassessmentofthemetabolicactivityofcyp2d6diplotypesandalleles‏ ‎‡A  In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles‏ ‎‡9  1‏
919 ‎‡a  invitroeffectofchlorambucilonhumangliomacelllinessf767andu87mgandhumanmicrovascularendothelialcellhmvecandendothelialprogenitorcellsecfcsinthecontextofplasmachlorambucilconcentrationsintumorbearingdogs‏ ‎‡A  In vitro effect of chlorambucil on human glioma cell lines (SF767 and U87-MG), and human microvascular endothelial cell (HMVEC) and endothelial progenitor cells (ECFCs), in the context of plasma chlorambucil concentrations in tumor-bearing dogs‏ ‎‡9  1‏
919 ‎‡a  impactofape1ref1redoxinhibitiononpancreatictumorgrowth‏ ‎‡A  Impact of APE1/Ref-1 redox inhibition on pancreatic tumor growth‏ ‎‡9  1‏
919 ‎‡a  humanizedbonemarrowmousemodelasapreclinicaltooltoassesstherapymediatedhematotoxicity‏ ‎‡A  Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity‏ ‎‡9  1‏
919 ‎‡a  exth13reductionoftumorburdenandhearinglosswithamultiplereceptortyrosinekinaseinhibitorbrigatinibinageneticallyengineeredmousemodelofneurofibromatosistype2‏ ‎‡A  EXTH-13. REDUCTION OF TUMOR BURDEN AND HEARING LOSS WITH A MULTIPLE RECEPTOR TYROSINE KINASE INHIBITOR BRIGATINIB IN A GENETICALLY ENGINEERED MOUSE MODEL OF NEUROFIBROMATOSIS TYPE 2‏ ‎‡9  1‏
919 ‎‡a  effectofcyp3a5expressiononvincristinemetabolismwithhumanlivermicrosomes‏ ‎‡A  Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes‏ ‎‡9  1‏
919 ‎‡a  efavirenzprimaryandsecondarymetabolisminvitroandinvivoidentificationofnovelmetabolicpathwaysandcytochromep4502a6astheprincipalcatalystofefavirenz7hydroxylation‏ ‎‡A  Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation‏ ‎‡9  1‏
919 ‎‡a  dualpi3kandwntpathwayinhibitionisasynergisticcombinationagainsttriplenegativebreastcancer‏ ‎‡A  Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer‏ ‎‡9  1‏
919 ‎‡a  differentialmodulationofudpglucuronosyltransferase1a1ugt1a1catalyzedestradiol3glucuronidationbytheadditionofugt1a1substratesandothercompoundstohumanlivermicrosomes‏ ‎‡A  Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes‏ ‎‡9  1‏
919 ‎‡a  differentialmodulationofudpglucuronosyltransferase1a1‏ ‎‡A  Differential modulation of UDP-glucuronosyltransferase 1A1‏ ‎‡9  1‏
919 ‎‡a  differentialmechanismbasedinhibitionofcyp3a4andcyp3a5byverapamil‏ ‎‡A  Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil‏ ‎‡9  1‏
919 ‎‡a  dextromethorphantodextrorphanurinarymetabolicratiodoesnotreflectdextromethorphanoralclearance‏ ‎‡A  Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance‏ ‎‡9  1‏
919 ‎‡a  cyp3a5genotypeanditsimpactonvincristinepharmacokineticsanddevelopmentofneuropathyinkenyanchildrenwithcancer‏ ‎‡A  CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer‏ ‎‡9  1‏
919 ‎‡a  contributionofnglucuronidationtoefavirenzeliminationinvivointhebasalandrifampininducedmetabolismofefavirenz‏ ‎‡A  Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz.‏ ‎‡9  1‏
919 ‎‡a  computationalapproachesthatpredictmetabolicintermediatecomplexformationwithcyp3a4+b5‏ ‎‡A  Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5).‏ ‎‡9  1‏
919 ‎‡a  comprehensiveassessmentofcytochromesp450andtransportergeneticswithendoxifenconcentrationduringtamoxifentreatment‏ ‎‡A  Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment‏ ‎‡9  1‏
919 ‎‡a  comparativemetaboliccapabilitiesofcyp3a4cyp3a5andcyp3a7‏ ‎‡A  Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.‏ ‎‡9  1‏
919 ‎‡a  combinationtherapyinaxenograftmodelofglioblastomaenhancementoftheantitumoractivityoftemozolomidebyanmdm2antagonist‏ ‎‡A  Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist‏ ‎‡9  1‏
919 ‎‡a  chiralplasmapharmacokineticsandurinaryexcretionofbupropionandmetabolitesinhealthyvolunteers‏ ‎‡A  Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers‏ ‎‡9  1‏
919 ‎‡a  chemopreventativecelecoxibfailstopreventschwannomaformationorsensorineuralhearinglossingeneticallyengineeredmurinemodelofneurofibromatosistype2‏ ‎‡A  Chemopreventative celecoxib fails to prevent schwannoma formation or sensorineural hearing loss in genetically engineered murine model of neurofibromatosis type 2.‏ ‎‡9  1‏
919 ‎‡a  atps75targetingthemdm2aktsignalingnetworkincombinationwithtemozolomideimprovesefficacyinectopicandorthotopicpatientderivedglioblastomaxenograftmodels‏ ‎‡A  ATPS-75TARGETING THE Mdm2-Akt SIGNALING NETWORK IN COMBINATION WITH TEMOZOLOMIDE IMPROVES EFFICACY IN ECTOPIC AND ORTHOTOPIC PATIENT-DERIVED GLIOBLASTOMA XENOGRAFT MODELS.‏ ‎‡9  1‏
919 ‎‡a  associationbetweennonalcoholichepaticsteatosisandhepaticcytochromep4503aactivity‏ ‎‡A  Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity‏ ‎‡9  1‏
919 ‎‡a  pilotstudyoftheimpactofgenotypeonnifedipinepharmacokineticswhenusedasatocolytic‏ ‎‡A  A pilot study of the impact of genotype on nifedipine pharmacokinetics when used as a tocolytic‏ ‎‡9  1‏
919 ‎‡a  phase2trialofdovitinibinbcgunresponsiveurothelialcarcinomawithfgfr3mutationsoroverexpressionhoosiercancerresearchnetworktrialhcrn12157‏ ‎‡A  A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157.‏ ‎‡9  1‏
996 ‎‡2  ISNI|0000000067406997‏
996 ‎‡2  ISNI|0000000390648478‏
996 ‎‡2  BIBSYS|12069065‏
996 ‎‡2  NUKAT|n 2006072724‏
996 ‎‡2  LC|n 93003936‏
996 ‎‡2  DNB|1227480717‏
996 ‎‡2  LC|no2014014147‏
996 ‎‡2  SUDOC|183448847‏
996 ‎‡2  DNB|1158088477‏
996 ‎‡2  ERRR|12293829‏
996 ‎‡2  SUDOC|252372085‏
996 ‎‡2  SUDOC|230220606‏
996 ‎‡2  NUKAT|n 2009096026‏
996 ‎‡2  LC|no2010115628‏
996 ‎‡2  ISNI|0000000082003301‏
996 ‎‡2  ISNI|0000000118772568‏
996 ‎‡2  DNB|135349125‏
996 ‎‡2  J9U|987007323639905171‏
996 ‎‡2  ISNI|0000000073823842‏
996 ‎‡2  LC|nb2011000479‏
996 ‎‡2  LC|nb2011012225‏
996 ‎‡2  J9U|987008916182305171‏
996 ‎‡2  ISNI|0000000084531298‏
996 ‎‡2  J9U|987007449402505171‏
996 ‎‡2  NLA|000035650404‏
996 ‎‡2  LC|n 98095236‏
996 ‎‡2  ISNI|0000000110568634‏
996 ‎‡2  SUDOC|034905324‏
996 ‎‡2  PLWABN|9810636308605606‏
996 ‎‡2  PLWABN|9810547597405606‏
996 ‎‡2  SUDOC|158488164‏
996 ‎‡2  NTA|380588773‏
996 ‎‡2  BNF|16621095‏
996 ‎‡2  LC|n 88611445‏
996 ‎‡2  SELIBR|341855‏
996 ‎‡2  LC|n 81047606‏
996 ‎‡2  NKC|jn20020717799‏
996 ‎‡2  NTA|072461292‏
996 ‎‡2  NSK|000639824‏
996 ‎‡2  PLWABN|9810661414905606‏
996 ‎‡2  NUKAT|nx2022586719‏
996 ‎‡2  J9U|987012503136405171‏
996 ‎‡2  ISNI|0000000114456779‏
996 ‎‡2  LC|nb2017022265‏
996 ‎‡2  J9U|987007449202005171‏
996 ‎‡2  DNB|172171083‏
996 ‎‡2  NUKAT|n 2018046639‏
996 ‎‡2  ISNI|0000000036717733‏
996 ‎‡2  W2Z|1542227328253‏
996 ‎‡2  CAOONL|ncf10129258‏
996 ‎‡2  SUDOC|184128226‏
996 ‎‡2  NSK|000062784‏
996 ‎‡2  ISNI|0000000062945609‏
996 ‎‡2  SZ|122108000‏
996 ‎‡2  DNB|1104286327‏
996 ‎‡2  DBC|87097969538452‏
996 ‎‡2  NSK|000615540‏
996 ‎‡2  LC|no2009140244‏
996 ‎‡2  LC|nb2008019790‏
996 ‎‡2  CAOONL|ncf11168204‏
996 ‎‡2  NUKAT|n 2012265883‏
996 ‎‡2  B2Q|0000473548‏
996 ‎‡2  NYNYRILM|1173‏
996 ‎‡2  SUDOC|089557131‏
996 ‎‡2  ISNI|000000011797693X‏
996 ‎‡2  LC|no2010115627‏
996 ‎‡2  ISNI|0000000077922776‏
996 ‎‡2  DNB|1028245114‏
996 ‎‡2  BNE|XX6247827‏
996 ‎‡2  NKC|mub2017951678‏
996 ‎‡2  DNB|124165885‏
996 ‎‡2  LC|n 94800289‏
996 ‎‡2  ISNI|000000006634283X‏
996 ‎‡2  ISNI|0000000115083716‏
996 ‎‡2  LC|n 83829126‏
996 ‎‡2  ISNI|0000000026909563‏
996 ‎‡2  BNF|13564854‏
996 ‎‡2  LC|nb2014011069‏
996 ‎‡2  LC|nb2009000633‏
996 ‎‡2  JPG|500008432‏
996 ‎‡2  LC|n 90646876‏
996 ‎‡2  ICCU|CUBV085437‏
996 ‎‡2  CAOONL|ncf10673814‏
996 ‎‡2  LC|n 90674075‏
996 ‎‡2  NLA|000035377373‏
996 ‎‡2  NDL|00453410‏
996 ‎‡2  ISNI|0000000114642096‏
996 ‎‡2  NDL|00558064‏
996 ‎‡2  LC|n 84038756‏
996 ‎‡2  PTBNP|1461046‏
996 ‎‡2  BIBSYS|90286509‏
996 ‎‡2  BIBSYS|90834795‏
996 ‎‡2  ISNI|0000000078718531‏
996 ‎‡2  NYNYRILM|234147‏
996 ‎‡2  BIBSYS|90851770‏
996 ‎‡2  BNF|15077766‏
996 ‎‡2  LC|n 2023180702‏
996 ‎‡2  DNB|1146311699‏
996 ‎‡2  BIBSYS|90110691‏
996 ‎‡2  W2Z|1488830535978‏
996 ‎‡2  ISNI|0000000084329903‏
996 ‎‡2  NTA|155684272‏
996 ‎‡2  DNB|1165800713‏
996 ‎‡2  ISNI|0000000032305651‏
996 ‎‡2  SUDOC|243094760‏
996 ‎‡2  NKC|jx20110825008‏
996 ‎‡2  ISNI|000000050133355X‏
996 ‎‡2  BNF|15094158‏
996 ‎‡2  NII|DA03346544‏
996 ‎‡2  PLWABN|9810554642705606‏
996 ‎‡2  LC|nr 96009089‏
996 ‎‡2  LC|nb 97091810‏
996 ‎‡2  BIBSYS|1535375968934‏
996 ‎‡2  NTA|10692091X‏
996 ‎‡2  J9U|987007386323105171‏
996 ‎‡2  LC|nb2009001206‏
996 ‎‡2  ISNI|0000000458511030‏
996 ‎‡2  ISNI|0000000436245018‏
996 ‎‡2  NKC|jo20241227751‏
996 ‎‡2  SUDOC|26798166X‏
996 ‎‡2  NUKAT|n 2012251524‏
996 ‎‡2  LC|n 2012054116‏
996 ‎‡2  J9U|987007455933905171‏
996 ‎‡2  LC|nb2011016697‏
996 ‎‡2  SIMACOB|61107555‏
996 ‎‡2  SUDOC|249994720‏
996 ‎‡2  LC|nb2003023577‏
996 ‎‡2  LC|n 90607116‏
996 ‎‡2  SUDOC|034056068‏
996 ‎‡2  ISNI|0000000120801495‏
996 ‎‡2  ISNI|0000000051654822‏
996 ‎‡2  NII|DA02600916‏
996 ‎‡2  J9U|987007351904905171‏
996 ‎‡2  LC|nb2018009845‏
996 ‎‡2  LC|no2003089214‏
996 ‎‡2  ISNI|0000000071512266‏
996 ‎‡2  NII|DA02844535‏
996 ‎‡2  NTA|126891516‏
996 ‎‡2  NUKAT|n 2022072620‏
996 ‎‡2  DNB|1047356929‏
996 ‎‡2  CAOONL|ncf11210540‏
996 ‎‡2  SUDOC|243662807‏
996 ‎‡2  LC|n 50080395‏
996 ‎‡2  NUKAT|n 00094191‏
996 ‎‡2  LC|n 78097051‏
996 ‎‡2  LNB|LNC10-000183564‏
996 ‎‡2  NTA|104762896‏
996 ‎‡2  NII|DA04971646‏
996 ‎‡2  LC|n 2003110534‏
996 ‎‡2  DNB|128352078‏
996 ‎‡2  J9U|987007421489505171‏
996 ‎‡2  NUKAT|n 2015181788‏
996 ‎‡2  LIH|LNB:B0_t__z_;=CA‏
996 ‎‡2  RERO|A012322120‏
996 ‎‡2  SUDOC|078810167‏
996 ‎‡2  BIBSYS|8019739‏
996 ‎‡2  BNC|981058517153406706‏
996 ‎‡2  W2Z|9024008‏
996 ‎‡2  BNF|14619140‏
996 ‎‡2  ISNI|0000000038482069‏
996 ‎‡2  LC|n 79032263‏
996 ‎‡2  LC|n 2011033282‏
996 ‎‡2  DNB|1345916736‏
996 ‎‡2  ISNI|0000000109988535‏
996 ‎‡2  CAOONL|ncf10678451‏
996 ‎‡2  LC|no2020014448‏
996 ‎‡2  LC|no2011176927‏
996 ‎‡2  W2Z|12047421‏
996 ‎‡2  KRNLK|KAC199700440‏
996 ‎‡2  LC|n 91022384‏
996 ‎‡2  ISNI|0000000079084067‏
996 ‎‡2  BIBSYS|10075553‏
996 ‎‡2  SKMASNL|vtls004936168‏
996 ‎‡2  N6I|vtls000035367‏
996 ‎‡2  LC|n 82152592‏
996 ‎‡2  DNB|141541911‏
996 ‎‡2  LC|nb2017014800‏
996 ‎‡2  NII|DA09435454‏
996 ‎‡2  LC|n 85130732‏
996 ‎‡2  J9U|987007369731705171‏
996 ‎‡2  NTA|072372397‏
996 ‎‡2  RERO|A022789465‏
996 ‎‡2  LC|nb2014007093‏
996 ‎‡2  DNB|1157196586‏
996 ‎‡2  NII|DA0177635X‏
996 ‎‡2  ERRR|12293817‏
996 ‎‡2  J9U|987007449799205171‏
996 ‎‡2  ISNI|0000000064745213‏
996 ‎‡2  LNB|LNC10-000094990‏
996 ‎‡2  ISNI|0000000378727034‏
996 ‎‡2  RERO|A003319994‏
996 ‎‡2  LC|n 84001300‏
996 ‎‡2  RERO|A013068432‏
996 ‎‡2  NII|DA17816657‏
996 ‎‡2  DNB|12213141X‏
996 ‎‡2  CAOONL|ncf11023870‏
996 ‎‡2  NLR|RU NLR AUTH 770126786‏
996 ‎‡2  ISNI|0000000498396903‏
996 ‎‡2  ISNI|0000000498396276‏
996 ‎‡2  BIBSYS|90168966‏
996 ‎‡2  SUDOC|119978407‏
996 ‎‡2  BNF|12277922‏
996 ‎‡2  RERO|A024752857‏
996 ‎‡2  BNC|981061202166406706‏
996 ‎‡2  NTA|242355145‏
996 ‎‡2  ISNI|0000000033357920‏
996 ‎‡2  DNB|136495389‏
996 ‎‡2  DNB|172171091‏
996 ‎‡2  ISNI|0000000119493317‏
996 ‎‡2  J9U|987007400188505171‏
996 ‎‡2  ISNI|0000000039380910‏
996 ‎‡2  J9U|987007320550505171‏
996 ‎‡2  ISNI|0000000053871089‏
996 ‎‡2  BIBSYS|1634281488371‏
996 ‎‡2  LC|n 84072686‏
996 ‎‡2  ISNI|0000000063294852‏
996 ‎‡2  NYNYRILM|257768‏
996 ‎‡2  LC|n 84150102‏
996 ‎‡2  NYNYRILM|257763‏
996 ‎‡2  ISNI|0000000051497767‏
996 ‎‡2  DE633|pe30093746‏
996 ‎‡2  LC|n 2002103407‏
996 ‎‡2  NII|DA02323430‏
996 ‎‡2  NYNYRILM|257764‏
996 ‎‡2  NUKAT|n 2008044085‏
996 ‎‡2  LC|nb2011017249‏
996 ‎‡2  SZ|118514091‏
996 ‎‡2  LC|no2013134389‏
996 ‎‡2  ISNI|0000000039005811‏
996 ‎‡2  LC|n 2013014445‏
996 ‎‡2  SUDOC|072477652‏
996 ‎‡2  LC|no 99047482‏
996 ‎‡2  ISNI|0000000021487621‏
996 ‎‡2  DNB|1027582656‏
996 ‎‡2  ISNI|000000008404406X‏
996 ‎‡2  NUKAT|n 99000761‏
996 ‎‡2  N6I|vtls001359510‏
996 ‎‡2  DNB|1030010870‏
996 ‎‡2  SUDOC|181385619‏
996 ‎‡2  LC|nb 98046421‏
996 ‎‡2  ISNI|0000000117332632‏
996 ‎‡2  BIBSYS|90399480‏
996 ‎‡2  NTA|085803693‏
996 ‎‡2  DNB|128978848‏
996 ‎‡2  DNB|1175589020‏
996 ‎‡2  RERO|A022861603‏
996 ‎‡2  ISNI|0000000076740129‏
996 ‎‡2  SUDOC|085958433‏
996 ‎‡2  CAOONL|ncf12123025‏
996 ‎‡2  RERO|A024819752‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏